奥沙利铂联合表柔比星、氟尿嘧啶治疗原发性肝癌

Treatment of Hepatocellular Carcinoma with Oxaliplatin Combinated with Epirubicine Fluorouracil

目的探讨奥沙利铂联合表柔比星、氟尿嘧啶治疗原发性肝癌的临床疗效和安全性。方法11例原发性肝癌患者采用注射用奥沙利铂130 mg/m2+5%葡萄糖注射液500 mL静脉滴注2 h,第1天;注射用盐酸表柔比星60 mg/m2+5%葡萄糖注射液50 mL静脉推注,第1天;氟尿嘧啶注射液2 600 mg/m2加入全自动注药泵中持续静脉输注46 h。每3周重复用药。结果11例患者中,部分缓解4例,稳定1例,进展5例,1例完成1周期化疗后放弃治疗。不良反应主要有:恶心、呕吐Ⅰ度5例、Ⅱ度2例,白细胞下降Ⅰ度2例、Ⅱ度6例,SGPT、SGOT上升Ⅰ度3例,周围神经感觉异常Ⅰ度2例,腹泻Ⅰ度1例,腹痛Ⅰ度1例,出现可逆性急性咽喉感觉障碍1例。结论奥沙利铂联合表柔比星、氟尿嘧啶治疗原发性肝癌有较好的疗效,不良反应少,值得临床进一步研究。

Objective To evaluate the efficacy and safety of Oxaliplatin combined with Epirubicin Fluorouracil in hepatocellular carcinoma. Methods Eleven patients with measurable disease received a 2-hour infusion of Oxaliplatin （130 mg/m^2） on day 1 ; Epirubicine （60 mg/m^2） iv on day 1; followed by a 46-hour continuous infusion of Fluorouracil（2 600 mg/m^2） every 3 weeks. Results There were 10 of the 11 patients could be evaluated for the responses and All for the safety. Four patients obtained partial response （PR） , 1 patient got stable disease （SD） , 5 patients showed a disease progression （PD） . The toxicities were mainly Grade Ⅰ nausea and vomit in 5 cases, GradeⅡ 2cases;Grade Ⅰ leucopenia 2 cases, Grade Ⅱ 6 cases ;SGPT SGOT Grade Ⅰ 3 cases; neurotoxicity Grade Ⅰ 2 cases etc. Conclusion Oxaliplatin and Epirubicine Fluorouracil is safe and effective for patients with hepatocellular carcinoma.